C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0322701 - e0322701

Published: May 7, 2025

Head and neck squamous cell carcinoma (HNSC) is a prevalent aggressive malignancy with poor prognosis, underscoring the need for novel biomarkers therapeutic strategies. This study investigates role of C16orf74 as potential diagnostic prognostic biomarker in HNSC. Bioinformatics analyses revealed that significantly overexpressed HNSC associated advanced disease stages, therapy resistance, shorter overall progression-free survival. A nomogram integrating expression clinicopathological features demonstrated robust predictive performance. Functional enrichment immune infiltration suggest high might contribute to an immunosuppressive tumor microenvironment by reducing key populations, such B cells, T natural killer which are critical anti-tumor immunity. Moreover, was inversely checkpoint immunotherapy response, highlighting its blockade (ICB) efficacy. Drug sensitivity identified agents, including arsenic trioxide, carmustine, vincristine, quercetin, carboplatin patients expression. These findings highlight target improve management.

Language: Английский

Preclinical in vitro models of HNSCC and their role in drug discovery - an emphasis on the cancer microenvironment and microbiota

Expert Opinion on Drug Discovery, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 21

Published: Dec. 15, 2024

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide. Treatment options patient outcomes have not improved significantly over past decades, increasing need for better preclinical models. Holistic approaches that include an intact functional immune compartment along with patient's individual tumor microbiome will help improve predictive value of novel drug efficacy.

Language: Английский